This biopharma stock has gained around 330% so far this year and is near record highs.
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $19.44, denoting a -0.26% change from the preceding trading day.
ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.